Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s):  AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.


CSE:AGN - Post by User

Post by C10H12N2on Dec 24, 2021 9:09am
159 Views
Post# 34260467

Algernon claimed to be a Phase II clinical trial company.

Algernon claimed to be a Phase II clinical trial company.The reality is Algernon still has not launched a real Phase II clinical trial. It has only conducted Phase II "studies" to study if it wants to run a real Phase II clinical trial. The IPF "study" is another nothing burger. Who cares if it's ever fully enrolled? That supposed catalyst sailed by a long time ago. The CEO claims Algernon lost a year with the IPF study. NO! The company as a whole has lost 4 years of dithering around with Private Placements and bogus studies all while the CEO runs around like he's getting things done. It's been a charade up to this point. Malhi made millions and Moreau drove the bus over the cliff AGAIN. Only to then reverse split the stock at all time lows. Now it's a waiting game to see if numb nuts can actually get the uplist to Nasdaq before he begins bleeding you dry with more capital raises. This time last year Moreau put out a nothing burger letter to shareholders thanking them for all their support. Moreau has been a loser for shareholders. It'll take a miracle for his track record in penny world to turn around. The guys a natural born loser.
<< Previous
Bullboard Posts
Next >>